Identification of 3‐(5‐cyano‐6‐oxo‐pyridin‐2‐yl)benzenesulfonamides as novel anticancer agents endowed with EGFR inhibitory activity
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202300449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Moataz A Shaldam und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt. Hauptthemen laut MEDLINE: Carbonic Anhydrases, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Deanship of Scientific Research at King Khalid University.
Abstract (Originalsprache)
New 5‐cyano‐6‐oxo‐pyridine‐based sulfonamides ( 6a–m and 8a–d ) were designed and synthesized to potentially inhibit both the epidermal growth factor receptor (EGFR) and carbonic anhydrase (CA), with anticancer properties. First, the in vitro anticancer activity of each target substance was tested using Henrietta Lacks cancer cell line and M.D. anderson metastasis breast cancer cell line cells. Then, the possible CA inhibition against the human CA isoforms I, II, and IX was investigated, together with the EGFR inhibitory activity, with the most powerful derivatives. The neighboring methoxy group may have had a steric effect on the target sulfonamides, which prevented them from effectively inhibiting the CA isoforms while effectively inhibiting the EGFR. The effects of the 5‐cyanopyridine derivatives 6e and 6l on cell‐cycle disruption and the apoptotic potential were then investigated. To investigate the binding mechanism and stability of the target molecules, thorough molecular modeling assessments, including docking and dynamic simulation, were performed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
- Department of Chemistry, University of Cambridge, Cambridge, UK.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, Cairo, Abbassia, Egypt.
- Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Sesto Fiorentino, Firenze, Italy.
- Department of Medical Physiology, College of Medicine, King Khalid University, Abha, Saudi Arabia.
ORCID-Profile: Moataz A Shaldam, Ahmed F Khalil, Claudiu T Supuran
Förderung
- Deanship of Scientific Research at King Khalid University
Zitieren
APA
Shaldam, M. A., Khalil, A. F., Almahli, H., Jaballah, M. Y., Angeli, A., Khaleel, E. F., Badi, R. M., Elkaeed, E. B., Supuran, C. T., Eldehna, W. M., & Tawfik, H. O. (2024). Identification of 3‐(5‐cyano‐6‐oxo‐pyridin‐2‐yl)benzenesulfonamides as novel anticancer agents endowed with EGFR inhibitory activity. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300449
Vancouver
Shaldam MA, Khalil AF, Almahli H, Jaballah MY, Angeli A, Khaleel EF, et al. Identification of 3‐(5‐cyano‐6‐oxo‐pyridin‐2‐yl)benzenesulfonamides as novel anticancer agents endowed with EGFR inhibitory activity. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202300449
BibTeX
@article{Shaldam2024,
author = {Shaldam, Moataz A and Khalil, Ahmed F and Almahli, Hadia and Jaballah, Maiy Y and Angeli, Andrea and Khaleel, Eman F and Badi, Rehab Mustafa and Elkaeed, Eslam B and Supuran, Claudiu T and Eldehna, Wagdy M and Tawfik, Haytham O},
title = {Identification of 3‐(5‐cyano‐6‐oxo‐pyridin‐2‐yl)benzenesulfonamides as novel anticancer agents endowed with EGFR inhibitory activity},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202300449}
}
EUVIMED